EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Using regadenoson for stress first-pass perfusion cardiac MR imaging: How, when, and why?

Bon-Marin Mulot, Hajer Chennoufi, Matthieu Demeyere, Sara Boccalini, Jean-Nicolas Dacher

Diagnostic and Interventional Imaging · 2026

DOI: 10.1016/j.diii.2026.01.001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostic and Interventional Imaging, 2026. Verfasst von Bon-Marin Mulot und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University Hospital of Rouen 76000 Rouen, France. Hauptthemen laut MEDLINE: Purines, Pyrazoles, Myocardial Perfusion Imaging, Adenosine A2 Receptor Agonists. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac magnetic resonance imaging (MRI) is a valuable tool for ruling out coronary artery disease, assessing cardiac viability, diagnosing myocardial ischemia, and providing prognostic information. Cardiac MRI, including vasodilator-induced first-pass perfusion imaging, is recommended for patients with a high probability of coronary disease, prior to revascularization, and when a viability assessment is necessary. Adenosine is the most commonly used vasodilating agent for stress cardiac MRI worldwide. However, regadenoson, which is an adenosine A2A receptor agonist, is a highly suitable alternative for stress cardiac MRI due to its kinetic properties, ease of use, single-dose administration, limited contraindications, and prognostic value. This technical note describes the characteristics and safety profile of regadenoson and discusses its application to cardiac MRI and reimbursement issues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PurinesPyrazolesMyocardial Perfusion ImagingAdenosine A2 Receptor AgonistsVasodilator AgentsExercise TestCoronary Artery DiseaseMagnetic Resonance ImagingHumansPerfusion Magnetic Resonance Imaging

Stichwörter der Autor:innen

Cardiac magnetic resonance imagingFirst-pass perfusionRegadenosonStress imaging

Substanzen

regadenosonPurinesPyrazolesAdenosine A2 Receptor AgonistsVasodilator Agents

Autor:innen und Institutionen

  • Department of Radiology, University Hospital of Rouen 76000 Rouen, France.
  • Department of Radiology, University Hospital of Rouen 76000 Rouen, France; UNIROUEN, INSERM U1096, UFR Santé, 76183, Rouen, France.
  • Department of Radiology, University Hospital of Rouen 76000 Rouen, France; UNIROUEN, INSERM U1096, UFR Santé, 76183, Rouen, France. Electronic address: jean-nicolas.dacher@chu-rouen.fr.

Zitieren

APA

Mulot, B. M., Chennoufi, H., Demeyere, M., Boccalini, S., & Dacher, J. N. (2026). Using regadenoson for stress first-pass perfusion cardiac MR imaging: How, when, and why?. Diagnostic and Interventional Imaging. https://doi.org/10.1016/j.diii.2026.01.001

Vancouver

Mulot BM, Chennoufi H, Demeyere M, Boccalini S, Dacher JN. Using regadenoson for stress first-pass perfusion cardiac MR imaging: How, when, and why?. Diagnostic and Interventional Imaging. 2026. doi:10.1016/j.diii.2026.01.001

BibTeX
@article{Mulot2026,
  author = {Mulot, Bon-Marin and Chennoufi, Hajer and Demeyere, Matthieu and Boccalini, Sara and Dacher, Jean-Nicolas},
  title = {Using regadenoson for stress first-pass perfusion cardiac MR imaging: How, when, and why?},
  journal = {Diagnostic and Interventional Imaging},
  year = {2026},
  doi = {10.1016/j.diii.2026.01.001}
}
Kostenlos starten →